Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Efeito da terapia Su Jok na amamentação (Sujok)

30 de outubro de 2026 atualizado por: Aysegul Kilicli

The Effect of Su Jok Therapy on Breastfeeding Success, Breastfeeding Self-Efficacy and Perception of Insufficient Milk After Caesarean Section in Primiparous

There are many alternative methods to increase breast milk. In the literature, studies on Su Jok therapy applications are limited and no studies on increasing breast milk have been found. In Korean language, 'Su' means hand and 'Jok' means foot. Su Jok therapy is defined as a modern acupressure/acupuncture interpretation that utilises the body's independent communication systems on the hands and feet by applying various techniques such as massage, moxa (heating), needles, magnets and seeds to the reflection points on the hands and feet. Su Jok is an integrated therapy that incorporates many tried and trusted methods of oriental medicine

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

There are many alternative methods to increase breast milk. In the literature, studies on Su Jok therapy applications are limited and no studies on increasing breast milk have been found. In Korean language, 'Su' means hand and 'Jok' means foot. Su Jok therapy is defined as a modern acupressure/acupuncture interpretation that utilises the body's independent communication systems on the hands and feet by applying various techniques such as massage, moxa (heating), needles, magnets and seeds to the reflection points on the hands and feet. Su Jok is an integrated therapy that incorporates many tried and trusted methods of oriental medicine.

Tipo de estudo

Intervencional

Inscrição (Real)

60

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Eyalet/Yerleşke
      • Sanliurfa, Eyalet/Yerleşke, Turquia (Türkiye), 63000
        • Şanlıurfa training and research hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

19 anos a 35 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • primiparous women giving birth by caesarean section,
  • women aged 19-35,
  • breastfeeding women

Exclusion Criteria:

  • those who refused to participate in the research

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: su jok therapy;

su jok therapy; application of seeds placed at certain points on the palm of the hand every day for the first ten days after birth, every day to be kept in the hand for 4 hours.

Su Jok Therapy

Sem intervenção: control group

control group, Su Jok will not be applied

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Breastfeeding Self-Efficacy Scale
Prazo: Pre-test; before the first Su Jok intervention

It was developed by Dennis (2003). Its Turkish validity and reliability was conducted by Aluş Tokat et al. (2010). The scale consists of 14 items and is in five-point Likert type. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

Pre-test; before the first Su Jok intervention
Breastfeeding Self-Efficacy Scale
Prazo: On the 3rd day after cesarean section (72 hours postpartum), before the 3rd Su Jok intervention.

It was developed by Dennis (2003). Its Turkish validity and reliability was conducted by Aluş Tokat et al. (2010). The scale consists of 14 items and is in five-point Likert type. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

On the 3rd day after cesarean section (72 hours postpartum), before the 3rd Su Jok intervention.
Breastfeeding Self-Efficacy Scale
Prazo: On the 10th day after cesarean section; after the last (10th) Su Jok intervention.

It was developed by Dennis (2003). Its Turkish validity and reliability was conducted by Aluş Tokat et al. (2010). The scale consists of 14 items and is in five-point Likert type. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

On the 10th day after cesarean section; after the last (10th) Su Jok intervention.
Breastfeeding Charting System: LATCH
Prazo: Pre-test; before the first Su Jok intervention

It was developed by Jensen et al. (1994). Its Turkish validity and reliability was performed by Yenal and Okumuş (2003). LATCH includes five evaluation criteria and consists of the first letters of the English equivalents of these criteria. In the LATCH Scoring System, 0, 1 or 2 points are given for each criterion A minimum score of 0 and a maximum score of 10 can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

Pre-test; before the first Su Jok intervention
Breastfeeding Charting System: LATCH
Prazo: On the 3rd day after cesarean section (72 hours postpartum), before the 3rd Su Jok intervention.

It was developed by Jensen et al. (1994). Its Turkish validity and reliability was performed by Yenal and Okumuş (2003). LATCH includes five evaluation criteria and consists of the first letters of the English equivalents of these criteria. In the LATCH Scoring System, 0, 1 or 2 points are given for each criterion. A minimum score of 0 and a maximum score of 10 can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

On the 3rd day after cesarean section (72 hours postpartum), before the 3rd Su Jok intervention.
Breastfeeding Charting System: LATCH
Prazo: On the 10th day after cesarean section; after the last (10th) Su Jok intervention.

It was developed by Jensen et al. (1994). Its Turkish validity and reliability was performed by Yenal and Okumuş (2003). LATCH includes five evaluation criteria and consists of the first letters of the English equivalents of these criteria. In the LATCH Scoring System, 0, 1 or 2 points are given for each criterion. A minimum score of 0 and a maximum score of 10 can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

On the 10th day after cesarean section; after the last (10th) Su Jok intervention.
Inadequate Milk Perception Scale
Prazo: Pre-test; before the first Su Jok intervention

The scale developed by McCarter-Spaulding and Kearney in 2001 consists of 6 questions to determine inadequate perception of breast milk. The first question questioning whether the mother perceives her milk as sufficient or not is in the form of 'yes' or 'no'. The other 5 questions aim to measure the perception of inadequacy of milk and are scored between 0-10. '0' indicates that milk is perceived as completely inadequate and "10" indicates that milk is perceived as completely adequate. The scale is scored between 0-50. A high score indicates an increased perception of milk sufficiency.

Pre-test; before the first Su Jok intervention
Inadequate Milk Perception Scale
Prazo: On the 3rd day after cesarean section (72 hours postpartum), before the 3rd Su Jok intervention.

The scale developed by McCarter-Spaulding and Kearney in 2001 consists of 6 questions to determine inadequate perception of breast milk. The first question questioning whether the mother perceives her milk as sufficient or not is in the form of 'yes' or 'no'. The other 5 questions aim to measure the perception of inadequacy of milk and are scored between 0-10. '0' indicates that milk is perceived as completely inadequate and "10" indicates that milk is perceived as completely adequate. The scale is scored between 0-50. A high score indicates an increased perception of milk sufficiency.

On the 3rd day after cesarean section (72 hours postpartum), before the 3rd Su Jok intervention.
Inadequate Milk Perception Scale; before the 3rd Su Jok intervention
Prazo: On the 10th day after cesarean section; after the last (10th) Su Jok intervention.

The scale developed by McCarter-Spaulding and Kearney in 2001 consists of 6 questions to determine inadequate perception of breast milk. The first question questioning whether the mother perceives her milk as sufficient or not is in the form of 'yes' or 'no'. The other 5 questions aim to measure the perception of inadequacy of milk and are scored between 0-10. '0' indicates that milk is perceived as completely inadequate and "10" indicates that milk is perceived as completely adequate. The scale is scored between 0-50. A high score indicates an increased perception of milk sufficiency.

On the 10th day after cesarean section; after the last (10th) Su Jok intervention.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: AYŞEGÜL KILIÇLI, Assisstan. Prof. PhD., Muş Alparslan University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

9 de outubro de 2024

Conclusão Primária (Real)

20 de janeiro de 2025

Conclusão do estudo (Real)

20 de janeiro de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

3 de outubro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

3 de outubro de 2024

Primeira postagem (Real)

8 de outubro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

30 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • MAUN

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

All

Prazo de Compartilhamento de IPD

15 October 2024- 15 October 2025

Critérios de acesso de compartilhamento IPD

15 October 2024- 15 October 2025

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • ANALYTIC_CODE
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever